Element Solutions Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? Element Solutions Inc. Common Stock trades at $35.59 (market cap $9.07B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Element Solutions Inc. Common Stock is the larger of the two by market cap, and Element Solutions Inc. Common Stock pays a 0.86% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Element Solutions Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ESI | TVTX | |
|---|---|---|
Market Cap | $9.07B | $4.88B |
Volume | 3,090,738 | 1,668,577 |
Sector | Basic Materials | Health |
52-Week High | $49.09 | $67.52 |
52-Week Low | $22.99 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.00B | $5.01B |
Dividend Yield | 0.86% | — |
Signals from Pluang's Aura AI — not financial advice
Element Solutions (ESI) trades at $37.20, up 2.06% today, with a neutral technical signal and bullish moving averages. The company shows strong earnings momentum with three consecutive quarterly beats and robust revenue growth from $2.55B in 2025 to $3.2B projected for 2026. Recent developments include the termination of the Solstice merger and focus on AI-driven demand and operational efficiencies.
ESI presents a mixed outlook with strong fundamental growth offset by valuation concerns. The stock trades at a premium P/E of 50.27 with analyst consensus target of $47.90 suggesting 28.8% upside. Key risks include inflation pressures and uneven industrial demand, while catalysts include continued AI adoption and data center expansion driving future performance.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Element Solutions provides specialty chemical products and technical services. Its solutions support electronics, communications, automotive systems, industrial surface finishing, and offshore energy.
Read more on ESI →Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →